ISRO has an ambitious lineup of upcoming space missions, demonstrating its commitment to advancing space exploration and ...
Bearish flow noted in Novartis (NVS) with 1,936 puts trading, or 3x expected. Most active are Apr-25 105 puts and Apr-25 110 puts, with total ...
On Thursday, the U.S. Food and Drug Administration (FDA) approved Novartis AG’s (NYSE:NVS) oral Fabhalta (iptacopan) for ...
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Phase III study showed sustained proteinuria reduction at one yea ...
Novartis’s (NVS) parasite-selective proteasome inhibitor with potent activity against kinetoplastid parasites was granted FDA orphan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results